Substituted pyrrolo[2,1-f][1,2,4]triazines as FGFR inhibitors

A compound represented by formula (I):

• or a pharmaceutically acceptable salt or stereoisomer thereof,
• wherein:
• R1 is H, halogen, C1-3 alkyl, C1-3 heteroalkyl, NH2, or OH, wherein the C1-3 alkyl or C1-3 heteroalkyl is optionally substituted with 1, 2, or 3 independently selected R substituents;
• R2 is H, F, Cl, Br, I, NH2, or OH;
• R3 is H, halogen, CN, C1-3 alkyl, C1-3 heteroalkyl, NH2, or OH, wherein the C1-3 alkyl or C1-3 heteroalkyl is optionally substituted with 1, 2, or 3 independently selected R substituents;
• R4 is H, halogen, CN, C1-3 alkyl, C1-3 heteroalkyl, NH2, or OH, wherein the C1-3 alkyl or C1-3 heteroalkyl is optionally substituted with 1, 2, or 3 independently selected R substituents;
• L is a single bond, C2-4 alkenylene, or C2-4 alkynylene;
• R5 is H, C1-3 alkyl, C1-3 heteroalkyl, C3-6 cycloalkyl, or 4- to 6-membered heterocycloalkyl, wherein the C1-3 alkyl, C1-3 heteroalkyl, C3-6 cycloalkyl, or 4- to 6-membered heterocycloalkyl is optionally substituted with 1, 2, or 3 independently selected R substituents;
• R6 is H, halogen, C1-3 alkyl, NH2, or OH, wherein the C1-3 alkyl is optionally substituted with 1, 2, or 3 independently selected R substituents;
• each R is independently F, Cl, Br, I, CN, CH3, CF3, NH2, N(CH3)2, OH, or OCH3;
• and
• m is 1 or 2;
• wherein each heteroatom or each heteroatomic group of each C1-3 heteroalkyl and each 4- to 6-membered heterocycloalkyl is 1, 2, or 3 heteroatoms or heteroatomic groups independently selected from the group consisting of N, —NH—, —O—, and —S—.